| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ANVSAnnovis Bio, Inc. | 84.81M | 3.20 | -0.00 | -189.15% | ||||
| CLNNClene Inc. | 60.19M | 5.11 | -0.90 | -47.71% | -142.5% | -17.38% | ||
| ABOSAcumen Pharmaceuticals, Inc. | 112.67M | 1.86 | -1.09 | -143.12% | 0.16 | |||
| BHVNBiohaven Ltd. | 1.58B | 11.92 | -1.28 | -198.83% | 0.09 | |||
| IKTInhibikase Therapeutics, Inc. | 200.09M | 1.65 | -1.42 | -100% | -65.37% | 0.00 | ||
| ALECAlector, Inc. | 198.66M | 1.82 | -1.48 | 3.6% | -156.03% | -186.68% | 0.34 | |
| CGTXCognition Therapeutics, Inc. | 121.82M | 1.38 | -1.62 | -76.61% | 0.04 | |||
| ATHEAlterity Therapeutics Limited | 60M | 3.31 | -2.90 | 35.32% | -330.63% | -73.75% | 0.00 |
| Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 142.66K | 132.4K | 201.17K | 108.54K | 0 | 4.34M | 5.12M | 3.92M | 4.02M | 5.44M |
| Revenue Growth % | -0.19% | -0.07% | 0.52% | -0.46% | -1% | - | 0.18% | -0.24% | 0.03% | 0.35% |
| Cost of Goods Sold | 22.81K | 21.33K | 21.8K | 29.7K | 112.43K | 360.03K | 364.67K | 285.07K | 214.3K | 127.52K |
| COGS % of Revenue | 0.16% | 0.16% | 0.11% | 0.27% | - | 0.08% | 0.07% | 0.07% | 0.05% | 0.02% |
| Gross Profit | 119.85K | 111.07K | 179.38K | 78.84K | -112.43K | 3.98M | 4.76M | 3.63M | 3.8M | 5.31M |
| Gross Margin % | 0.84% | 0.84% | 0.89% | 0.73% | - | 0.92% | 0.93% | 0.93% | 0.95% | 0.98% |
| Gross Profit Growth % | 2.49% | -0.07% | 0.62% | -0.56% | -2.43% | 36.4% | 0.2% | -0.24% | 0.05% | 0.4% |
| Operating Expenses | 8.49M | 6.77M | 11.1M | 12.47M | 10.07M | 19.16M | 20.26M | 18.24M | 23.41M | 19.89M |
| OpEx % of Revenue | 59.5% | 51.15% | 55.16% | 114.92% | - | 4.41% | 3.95% | 4.66% | 5.82% | 3.66% |
| Selling, General & Admin | 3.59M | 3.95M | 4.32M | 4.28M | 3.33M | 6.87M | 5.51M | 5.04M | 4.76M | 5.48M |
| SG&A % of Revenue | 25.15% | 29.81% | 21.47% | 39.42% | - | 1.58% | 1.08% | 1.29% | 1.18% | 1.01% |
| Research & Development | 9.59M | 5.7M | 6.7M | 12.98M | 10.1M | 12.28M | 14.75M | 13.2M | 18.64M | 14.4M |
| R&D % of Revenue | 67.19% | 43.06% | 33.29% | 119.62% | - | 2.83% | 2.88% | 3.37% | 4.64% | 2.65% |
| Other Operating Expenses | -241.95K | -241.89K | 0 | -4.79M | -3.36M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.59M | -6.88M | -7.77M | -12.71M | -10.41M | -15.18M | -15.5M | -14.64M | -19.6M | -14.57M |
| Operating Margin % | -60.19% | -51.98% | -38.62% | -117.14% | - | -3.5% | -3.03% | -3.74% | -4.88% | -2.68% |
| Operating Income Growth % | 0.18% | 0.2% | -0.13% | -0.64% | 0.18% | -0.46% | -0.02% | 0.06% | -0.34% | 0.26% |
| EBITDA | -8.56M | -6.86M | -7.75M | -12.68M | -10.3M | -15.16M | -15.45M | -14.6M | -19.57M | -14.55M |
| EBITDA Margin % | -60.03% | -51.82% | -38.52% | -116.86% | - | -3.49% | -3.02% | -3.73% | -4.87% | -2.67% |
| EBITDA Growth % | 0.18% | 0.2% | -0.13% | -0.64% | 0.19% | -0.47% | -0.02% | 0.05% | -0.34% | 0.26% |
| D&A (Non-Cash Add-back) | 22.81K | 21.33K | 21.8K | 29.7K | 112.43K | 18.66K | 54.21K | 37.85K | 35.34K | 28.31K |
| EBIT | -8.59M | -6.88M | -8.2M | -12.8M | -13.46M | -15.18M | -17.45M | -14.64M | -19.61M | -14.66M |
| Net Interest Income | 0 | 0 | 0 | 0 | 17.12K | 20.68K | 2.5K | 16.44K | 268.42K | 446.29K |
| Interest Income | 142.66K | 132.4K | 201.17K | 108.54K | 17.12K | 20.68K | 2.5K | 16.44K | 268.42K | 446.29K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 811.97K | -786.28K | -127.86K | 324.64K | 428.68K | -133.04K | 2.72M | 904.68K | 524.33K | 2.49M |
| Pretax Income | -7.73M | -7.54M | -8.27M | -12.34M | -10.06M | -15.31M | -12.78M | -13.7M | -19.08M | -12.08M |
| Pretax Margin % | -54.18% | -56.97% | -41.09% | -113.67% | - | -3.53% | -2.49% | -3.5% | -4.75% | -2.22% |
| Income Tax | 0 | 660.21K | -495.44K | -376.03K | -362.19K | 0 | 70.01K | 104.46K | 46.09K | 68.06K |
| Effective Tax Rate % | 1% | 1% | 1% | 0.97% | 1% | 1% | 1.01% | 1.01% | 1% | 1.01% |
| Net Income | -7.73M | -7.54M | -8.27M | -11.96M | -10.06M | -15.31M | -12.85M | -13.81M | -19.12M | -12.15M |
| Net Margin % | -54.18% | -56.97% | -41.09% | -110.21% | - | -3.53% | -2.51% | -3.53% | -4.76% | -2.23% |
| Net Income Growth % | -0.31% | 0.02% | -0.1% | -0.45% | 0.16% | -0.52% | 0.16% | -0.07% | -0.39% | 0.36% |
| Net Income (Continuing) | -7.73M | -7.54M | -8.27M | -12.34M | -13.46M | -15.31M | -12.85M | -13.81M | -19.12M | -12.15M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -8.70 | -8.46 | -9.30 | -11.64 | -6.48 | -5.40 | -3.18 | -3.42 | -3.12 | -1.14 |
| EPS Growth % | -0.24% | 0.03% | -0.1% | -0.25% | 0.44% | 0.17% | 0.41% | -0.08% | 0.09% | 0.63% |
| EPS (Basic) | -8.70 | -8.46 | -9.30 | -11.64 | -6.48 | -5.40 | -3.18 | -3.42 | -3.12 | -1.14 |
| Diluted Shares Outstanding | 889.82K | 889.82K | 889.82K | 1.03M | 1.49M | 2.83M | 4.01M | 4.05M | 6.08M | 10.66M |
| Basic Shares Outstanding | 888.51K | 889.82K | 888.79K | 1.03M | 1.49M | 2.83M | 4.01M | 4.05M | 6.08M | 10.66M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 33.66M | 25.25M | 18.65M | 19.86M | 13.23M | 33.49M | 41.14M | 27.05M | 19.04M | 45.87M |
| Cash & Short-Term Investments | 28.59M | 21.93M | 15.25M | 14.4M | 9.2M | 28.12M | 34.81M | 15.77M | 12.64M | 40.66M |
| Cash Only | 28.59M | 21.88M | 15.24M | 14.4M | 9.2M | 28.12M | 34.81M | 15.77M | 12.64M | 33.16M |
| Short-Term Investments | 0 | 43.99K | 9.51K | 0 | 0 | 0 | 0 | 0 | 0 | 7.5M |
| Accounts Receivable | 4.79M | 3.04M | 3.15M | 4.83M | 61.32K | 4.13M | 4.67M | 8.65M | 4.04M | 3.94M |
| Days Sales Outstanding | 12.25K | 8.37K | 5.72K | 16.24K | - | 347.06 | 332.65 | 806.07 | 367.03 | 264.25 |
| Inventory | 251.22K | 241.63K | 256.82K | 621.74K | 567.88K | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 4.02K | 4.14K | 4.3K | 7.64K | 1.84K | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 290 | 10.03K | 2.84M | 160.67K | 66.19K | 56.6K | 40.67K | 41.81K |
| Total Non-Current Assets | 68.21K | 30.82K | 71.42K | 48.75K | 71.37K | 96.81K | 218.52K | 268.86K | 186.88K | 155.17K |
| Property, Plant & Equipment | 24.23K | 30.82K | 71.42K | 48.75K | 71.37K | 96.81K | 218.52K | 268.86K | 186.88K | 155.17K |
| Fixed Asset Turnover | 5.89x | 4.30x | 2.82x | 2.23x | - | 44.83x | 23.45x | 14.57x | 21.51x | 35.05x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 43.99K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | -30.82K | -71.42K | -48.75K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 33.73M | 25.28M | 18.73M | 19.91M | 13.3M | 33.59M | 41.36M | 27.32M | 19.22M | 46.03M |
| Asset Turnover | 0.00x | 0.01x | 0.01x | 0.01x | - | 0.13x | 0.12x | 0.14x | 0.21x | 0.12x |
| Asset Growth % | -0.19% | -0.25% | -0.26% | 0.06% | -0.33% | 1.52% | 0.23% | -0.34% | -0.3% | 1.39% |
| Total Current Liabilities | 2.36M | 1.59M | 2.64M | 3.32M | 2.71M | 3.07M | 5.82M | 4.38M | 5.37M | 3.53M |
| Accounts Payable | 311.72K | 65.05K | 1.33M | 1.69M | 954.03K | 1.45M | 2.64M | 1.72M | 581.14K | 538.28K |
| Days Payables Outstanding | 4.99K | 1.11K | 22.33K | 20.82K | 3.1K | 1.47K | 2.64K | 2.2K | 989.79 | 1.54K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | -32.88K | 0 | -57.63K | -107.18K | 0 | 0 |
| Other Current Liabilities | 0 | 698.04K | 11.19K | 11.72K | 43.84K | 33.84K | 2.5M | 169.02K | 4.12M | 876.05K |
| Current Ratio | 14.28x | 15.88x | 7.06x | 5.98x | 4.88x | 10.92x | 7.07x | 6.17x | 3.54x | 12.98x |
| Quick Ratio | 14.17x | 15.72x | 6.96x | 5.79x | 4.67x | 10.92x | 7.07x | 6.17x | 3.54x | 12.98x |
| Cash Conversion Cycle | 11.28K | 11.39K | -12.31K | 3.06K | - | - | - | - | - | - |
| Total Non-Current Liabilities | 470 | 440 | 916 | 34.98K | 42.38K | 47.67K | 73.61K | 122.71K | 51.91K | 88.55K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 868 | 37.9K | 59.86K | 103.21K | 51.91K | 88.55K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 470 | 440 | 916 | 34.98K | 41.51K | 9.77K | 13.75K | 19.5K | 0 | 0 |
| Total Liabilities | 2.36M | 1.59M | 2.64M | 3.36M | 2.76M | 3.12M | 5.89M | 4.5M | 5.43M | 3.62M |
| Total Debt | 0 | 0 | 0 | 0 | 33.75K | 65.65K | 117.49K | 210.38K | 159.04K | 155.46K |
| Net Debt | -28.59M | -21.88M | -15.24M | -14.4M | -9.16M | -28.05M | -34.69M | -15.56M | -12.48M | -33M |
| Debt / Equity | - | - | - | - | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 31.37M | 23.69M | 16.08M | 16.55M | 10.55M | 30.47M | 35.47M | 22.81M | 13.8M | 42.4M |
| Equity Growth % | -0.2% | -0.24% | -0.32% | 0.03% | -0.36% | 1.89% | 0.16% | -0.36% | -0.4% | 2.07% |
| Book Value per Share | 35.25 | 26.62 | 18.07 | 16.13 | 7.07 | 10.77 | 8.85 | 5.64 | 2.27 | 3.98 |
| Total Shareholders' Equity | 31.37M | 23.69M | 16.08M | 16.55M | 10.55M | 30.47M | 35.47M | 22.81M | 13.8M | 42.4M |
| Common Stock | 146.88M | 144.02M | 143.91M | 156.63M | 160.7M | 197.45M | 213.79M | 213.97M | 223.15M | 262.95M |
| Retained Earnings | -124.88M | -122.65M | -129.58M | -141.24M | -151.02M | -169.73M | -181.88M | -195.13M | -214.16M | -225.89M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 9.36M | 2.32M | 1.75M | 1.16M | 866.12K | 2.75M | 3.57M | 3.97M | 4.81M | 5.34M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -7.42M | -5.87M | -6.25M | -13.95M | -9.43M | -17.33M | -12.34M | -20.04M | -12.61M | -11.45M |
| Operating CF Margin % | -52% | -44.3% | -31.04% | -128.57% | - | -3.99% | -2.41% | -5.12% | -3.14% | -2.11% |
| Operating CF Growth % | 0.32% | 0.21% | -0.06% | -1.23% | 0.32% | -0.84% | 0.29% | -0.62% | 0.37% | 0.09% |
| Net Income | -7.73M | -7.54M | -8.27M | -12.34M | -10.06M | -15.31M | -12.85M | -13.81M | -19.12M | -12.15M |
| Depreciation & Amortization | 22.81K | 21.33K | 21.8K | 29.7K | 112.43K | 75.37K | 54.21K | 102.26K | 147.53K | 139.72K |
| Stock-Based Compensation | -16.5K | 24.46K | 764.54K | 89.14K | -12.02K | 1.88M | 1.51M | 966.57K | 881.95K | 979.92K |
| Deferred Taxes | -934.22K | 631.56K | -486.42K | -493.02K | -250.96K | 2.33M | -1.06M | 2.99M | 0 | 0 |
| Other Non-Cash Items | -16.5K | 24.46K | 764.54K | 89.14K | -12.02K | -2.1M | 455.57K | -6.35M | -261.15K | 190.62K |
| Working Capital Changes | 1.26M | 975.19K | 956.09K | -1.33M | 791.13K | -4.22M | -447.68K | -3.94M | 5.75M | -613.68K |
| Change in Receivables | 1.73M | 1.75M | -116.84K | -1.68M | 4.77M | -4.22M | -447.68K | -3.94M | 4.62M | 104.07K |
| Change in Inventory | -127.72K | -4.07K | 18.99K | -662.93K | 648.57K | 191.13K | -2.21M | 2.45M | 0 | 0 |
| Change in Payables | -403.45K | -856.13K | 1.16M | 662.93K | -648.57K | 432.9K | 2.6M | -1.56M | 1.1M | 0 |
| Cash from Investing | -833 | -27.92K | -18.42K | -7.02K | -16.74K | -10.47K | -89.15K | -36.46K | -5.72K | -7.5M |
| Capital Expenditures | -2.31K | -27.92K | -62.41K | -7.02K | -16.74K | -10.47K | -89.15K | -7.31K | -5.72K | 0 |
| CapEx % of Revenue | 0.02% | 0.21% | 0.31% | 0.06% | - | 0% | 0.02% | 0% | 0% | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 1.47K | 0 | 43.99K | 0 | 0 | 0 | 0 | -29.15K | 0 | 0 |
| Cash from Financing | 152.6K | -159.56K | -107.68K | 12.72M | 3.98M | 36.69M | 16.3M | 124.34K | 9.22M | 39.67M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 152.6K | -159.56K | -107.68K | -362.32K | -292.77K | -2.49M | -836.97K | -132.41K | -918.02K | -2.77M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -7.42M | -5.89M | -6.31M | -13.96M | -9.45M | -17.34M | -12.43M | -20.04M | -12.61M | -11.45M |
| FCF Margin % | -52.02% | -44.51% | -31.35% | -128.64% | - | -4% | -2.43% | -5.12% | -3.14% | -2.11% |
| FCF Growth % | 0.32% | 0.21% | -0.07% | -1.21% | 0.32% | -0.84% | 0.28% | -0.61% | 0.37% | 0.09% |
| FCF per Share | -8.34 | -6.62 | -7.09 | -13.60 | -6.33 | -6.13 | -3.10 | -4.95 | -2.07 | -1.07 |
| FCF Conversion (FCF/Net Income) | 0.96x | 0.78x | 0.76x | 1.17x | 0.94x | 1.13x | 0.96x | 1.45x | 0.66x | 0.94x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -21.93% | -27.4% | -41.57% | -73.3% | -74.23% | -74.65% | -38.97% | -47.38% | -104.47% | -43.23% |
| Return on Invested Capital (ROIC) | -184.6% | -225.45% | -439.72% | -635.59% | -441.32% | -598.31% | -726.68% | -273.44% | -343.18% | -203.97% |
| Gross Margin | 84.01% | 83.89% | 89.16% | 72.64% | - | 91.7% | 92.88% | 92.72% | 94.67% | 97.66% |
| Net Margin | -5418.28% | -5696.6% | -4108.75% | -11020.84% | - | -352.78% | -250.75% | -352.54% | -475.79% | -223.35% |
| Debt / Equity | - | - | - | - | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.00x |
| FCF Conversion | 0.96x | 0.78x | 0.76x | 1.17x | 0.94x | 1.13x | 0.96x | 1.45x | 0.66x | 0.94x |
| Revenue Growth | -19.33% | -7.19% | 51.95% | -46.05% | -100% | - | 18.06% | -23.56% | 2.63% | 35.32% |
Alterity Therapeutics Limited (ATHE) reported $9.5M in revenue for fiscal year 2025. This represents a 4967% increase from $0.2M in 2012.
Alterity Therapeutics Limited (ATHE) grew revenue by 35.3% over the past year. This is strong growth.
Alterity Therapeutics Limited (ATHE) reported a net loss of $31.3M for fiscal year 2025.
Alterity Therapeutics Limited (ATHE) has a return on equity (ROE) of -43.2%. Negative ROE indicates the company is unprofitable.
Alterity Therapeutics Limited (ATHE) had negative free cash flow of $23.7M in fiscal year 2025, likely due to heavy capital investments.